IGHE and COVID-19: 21 patients with COVID-19 used biologicals: 15 (71%) anti-IL-5 or anti-IL5R drugs (mepolizumab n = 13; benralizumab n = 2) and 6 (29%) anti-IgE drug (omalizumab).